The Prognostic Value For Determining Of Galectin-3’ Level In Patients With Metabolic Syndrome And Nonalcoholic Fatty Liver Disease

Research Article
O. Drapkina., T. Deeva and V. Ivashkin
Galectin-3, fibrosis, metabolic syndrome, chronic heart failure, nonalcoholic fatty liver disease, hepatic steatosis, steatosis of the pancreas.

Aims: To evaluate the level of galectin-3 in patients with metabolic syndrome (MetS). Methods: The research of level of galectin-3 has included 76 patients, 43 patients with MetS, 72, 1% (31 out of 43) from them - with nonalcoholic fatty liver disease (NAFLD), 33 patients without MetS and NAFLD. Results: Аn average level of galectin-3 in the group with MetS was reliably higher compared with the group without MetS, p=0,006. Positive correlation was revealed between the level of galectin-3 and 1) Left ventricle hypertrophy - LVH (r=0,30), 2)Chronic heart failure - CHF (r=0,35), 3) Coronary heart disease (r=0,34), 4) Fraction of fibrosis of the heart (r=0,24) 5) Hepatic (r=0,43) and pancreatic (r=0,24) steatosis, 6) NAFLD fibrosis score (r=0,30), 7) The level of leptin, p<0,05. Conclusions. The research revealed the relationship between the level of galectin-3 and the diseases, closely associated with MetS, namely LVH, CHF, fraction of fibrosis in the heart, NAFLD, pancreatic steatosis. The level of galectin-3 was higher in patients with MetS, which can be seen as evidence of more distinct fibrosis of the heart and liver in this group of patients. The galectin-3 can be used as an additional criterion for the diagnosis of cardiovascular diseases and NAFLD.